Get the app
US › Healthcare

Myriad Genetics Inc (MYGN)

US · Healthcare · Diagnostics & Research

$4.14+7.25%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$190.7M
Revenue YoY
-10.5%
Net profit
$-43.2M
EPS
$-0.33
EPS estimate
$-0.08
Net margin
-22.7%

EPS came in at -0.33 against a street estimate of -0.08 — a miss of 312.5%.

Key statistics

Market cap
$321.4M
Forward P/E
54.1
P/B
1.00
Book value
$3.18
EPS (TTM)
$-1.25
52-week high
$8.59
52-week low
$2.74
50-day MA
$4.32
200-day MA
$5.03
Beta
1.64

Analyst view

Analysts rate Myriad Genetics Inc a hold (6 buy, 6 hold, 3 sell out of 15) with an average price target of $3.37.

Shareholding

Insiders
3.96%
Institutions
96.96%

Largest institutional holders

FundStake
BlackRock Inc9.30%
Millennium Management LLC6.93%
D. E. Shaw & Co LP4.79%
State Street Corp4.63%
Vanguard Capital Management, LLC4.11%
Morgan Stanley - Brokerage Accounts3.31%
Vanguard Portfolio Management, LLC2.70%
The Goldman Sachs Group Inc2.48%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Myriad Genetics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.